Multiple Myeloma: all 3,712 studies
Page 5 of 38. Open to participants first (752), then studies with results posted, then the rest; newest registration first within each.
- Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific AntibodiesRecruitingNCT06398457Early Phase 1
- Wisconsin Ginseng for Decreasing Cancer Related FatigueRecruitingNCT06395441Phase 3
- PET Imaging Study of 68Ga-NB381 in Multiple MyelomaRecruitingNCT06385652Early Phase 1
- IMMUNOPLANT for Newly Diagnosed Multiple MyelomaRecruitingNCT06376526Phase 2
- Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT06375044Phase 1
- A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.Not yet recruitingNCT06369935
- Study of SYS6020 in BCMA-positive Multiple MyelomaNot yet recruitingNCT06359509Early Phase 1
- Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary MalignancyRecruitingNCT06357754
- Early Assessment of Cardiac Function After Treatment With CAR-T CellsRecruitingNCT06350994
- Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple MyelomaRecruitingNCT06348108Phase 1
- Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)RecruitingNCT06340646Not applicable
- Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCLNot yet recruitingNCT06333509Phase 1/2
- Study on the Efficacy and Safety of Low-dose CTX as Maintenance Therapy for MM Unsuitable for TransplantationRecruitingNCT06324266Phase 2/3
- Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone DiseaseNot yet recruitingNCT06314698Phase 3
- Detecting Minimal Residual Diseases (MRD) and Monitoring Clonal Evolution Using Ultrasensitive Chromosomal Aberrations Detection (UCAD) in Multiple MyelomaRecruitingNCT06302699
- To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT06298266Early Phase 1
- Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT06297226Phase 2
- DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology ClinicsRecruitingNCT06296368Not applicable
- A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple MyelomaRecruitingNCT06296121Phase 3
- A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)RecruitingNCT06292780Phase 1/2
- Comparison of the Complications in Multiple Myeloma Patients Who Received Autologous Stem Cell Transplantation Between in HEPA-filtered Room and Non-HEPA-filtered RoomNot yet recruitingNCT06286241
- Registry of Haploidentical Hematopoietic Stem Cell Transplantation in Adult With Hematologic DiseaseNot yet recruitingNCT06286228
- A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical TrialsRecruitingNCT06285318
- Two Schemes Response in Multiple MyelomaRecruitingNCT06284395
- Prehab Prior to Stem Cell Transplantation in Multiple MyelomaRecruitingNCT06280924Not applicable
- UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple MyelomaRecruitingNCT06279026Not applicable
- A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL StudyRecruitingNCT06271252Phase 1
- Hypofractionation (Radiation) Trial for Multiple MyelomaRecruitingNCT06270888Phase 1
- RAT-HEMATO : Return to Work After Malignant HemopathyRecruitingNCT06262789Not applicable
- LI-TASTE Study: Light for TasteNot yet recruitingNCT06258096Not applicable
- Clinical Study of Reduced-dose Pomalidomide and Cyclophosphamide Combined With Dexamethasone in the Treatment of Patients With Debilitating RRMMRecruitingNCT06255847Phase 2
- Biomechanical and Metabolic Assessment Pre and Post Vertebroplasty in Multiple Myeloma Patients With Vertebral CollapseRecruitingNCT06255639
- Dara-PD in the Treatment of Patients With First Relapse of Multiple MyelomaRecruitingNCT06252792
- Plan Development for Giving Teclistamab in the Outpatient SettingRecruitingNCT06251076Phase 4
- European Rare Blood Disorders Platform (ENROL)RecruitingNCT06250595
- ICOPE Program Feasibility in the Management of Myeloma PatientsRecruitingNCT06247189Not applicable
- Mitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple MyelomaRecruitingNCT06246162Phase 1/2
- Bortezomib-bendamustine-melphalan vs Melphalan for Multiple MyelomaRecruitingNCT06245629
- Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple MyelomaNot yet recruitingNCT06242249Phase 1/2
- European Myeloma Network (EMN) Sample ProjectRecruitingNCT06237803
- The Unmet Needs of Cancer Survivors in Ausl IRCCS Reggio EmiliaRecruitingNCT06236373
- A Study of GC012F in Patients With Relapsed/Refractory Multiple MyelomaRecruitingNCT06235229Phase 1/2
- A Study of MBS314 in Participants With Relapsed/Refractory Multiple Myeloma.RecruitingNCT06232096Phase 1/2
- The Prognostic Value of CPCs Quantified by Flow Cytometry in Patients With Multiple Myeloma: a Prospective, Multicenter Clinical TrialRecruitingNCT06228794
- A Trial of Selinexor, Ruxolitinib and MethylprednisoloneRecruitingNCT06225310Phase 1
- Preliminary Assessment of [18F]BL40 in PET/CT ScansRecruitingNCT06224309
- A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT06223646Phase 1/2
- Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple MyelomaRecruitingNCT06209606Early Phase 1
- Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple MyelomaRecruitingNCT06207799Phase 2
- A Clinical Study on the Whole-course Management (BCD-KPD-AutoHSCT) Scheme for Patients With RIMMRecruitingNCT06203145Not applicable
- Safety and Efficacy of Anti-FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)RecruitingNCT06196255Phase 1/2
- Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUSRecruitingNCT06189833Phase 2
- FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)RecruitingNCT06187441Phase 3
- Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple MyelomaRecruitingNCT06185751Phase 1
- Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple MyelomaRecruitingNCT06182774Phase 3
- OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMMRecruitingNCT06182696Phase 1/2
- All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple MyelomaRecruitingNCT06158412Phase 2
- DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple MyelomaRecruitingNCT06158269Phase 2
- Study for Validation of Target Therapy in Multiple Myeloma Cells From Patients With miRNAs Released From B Cells, and Study of the Bone Marrow Tumor Microenvironment (Microenvironment of MM)RecruitingNCT06154317
- A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple MyelomaRecruitingNCT06153251Phase 1
- MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)RecruitingNCT06152575Phase 3
- Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple MyelomaRecruitingNCT06149910
- Remote Monitoring With Health-Coaching to Improve Quality of Life in Older Patients With Multiple MyelomaRecruitingNCT06145581Not applicable
- Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal FailureRecruitingNCT06142396Early Phase 1
- Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple MyelomaRecruitingNCT06140966Phase 2
- Elranatamab in R/R Multiple MyelomaRecruitingNCT06138275Phase 2
- Evaluation of the Role of Connected Scales in the Therapeutic Care of Hematology PatientsRecruitingNCT06133426Not applicable
- Safety and Efficacy of APRIL-BAFF-Bicephali CAR-T in Relapsed, Refractory Multiple MyelomaRecruitingNCT06132711Phase 1/2
- A Study of CM313 in Subjects With Relapsed or Refractory Multiple MyelomaNot yet recruitingNCT06126237Phase 1/2
- A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple MyelomaRecruitingNCT06121843Phase 1
- IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic CancersRecruitingNCT06119685Phase 1/2
- Lapelga vs GastrofilNot yet recruitingNCT06116734Phase 3
- A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple MyelomaRecruitingNCT06115135Phase 2
- A Perspective Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial TreatmentRecruitingNCT06109233
- Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple MyelomaRecruitingNCT06107738Phase 2
- AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple MyelomaRecruitingNCT06106945Phase 1/2
- Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple MyelomaRecruitingNCT06105554Phase 1/2
- 18F-Fluciclovine PET/CT in Multiple MyelomaRecruitingNCT06103838Phase 2
- Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)RecruitingNCT06100237Phase 2
- Individualized Dynamic Frailty-tailored Therapy (DynaFiT) in Elderly Patients With NDMMRecruitingNCT06099912
- Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)RecruitingNCT06087653Phase 1/2
- A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple MyelomaRecruitingNCT06084962Phase 1
- A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)RecruitingNCT06083922Phase 2
- A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple MyelomaRecruitingNCT06083207Phase 1/2
- A Cross-sectional Study on the Positive Rate of M Protein Based on a Highly Sensitive Serum M Protein Detection Method.RecruitingNCT06082284
- the Safety and Efficacy of SENL103 Autologous T Cell InjectionRecruitingNCT06067581Early Phase 1
- A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell TherapyRecruitingNCT06066346Phase 2
- Efficacy and Safety of PEG-rhG-CSF Injection for Neutrophil Reconstitution Following AHSCT in Lymphoma/Multiple MyelomaRecruitingNCT06060080Not applicable
- Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)RecruitingNCT06057402Phase 4
- A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)RecruitingNCT06055894Not applicable
- Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART StudyRecruitingNCT06052826Phase 2
- A Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple MyelomaRecruitingNCT06049290Phase 1/2
- Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple MyelomaRecruitingNCT06048250Phase 1
- To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCLRecruitingNCT06045091Early Phase 1
- Cardiac Toxicity and Prognostic Value of New Echocardiographic Indicators in the Treatment of Primary Multiple MyelomaRecruitingNCT06039735
- Real-World Mapping Antithrombotic Regimens in MM Patients on TreatmentRecruitingNCT06028087
- Self-administration of Subcutaneous Elranatamab in the Patients' Homes.RecruitingNCT06015542Phase 2
- Assessing the Relationship Between Hypoxia and the Immune Environment in Myeloma Patients (CHIME)Not yet recruitingNCT06007989
- A Clinical Study to Evaluate the Safety and Efficacy of BCMA-GPRC5D CAR-T in Patients With Relapsed/Refractory Multiple Myeloma Who Received Three or More Lines of TherapyRecruitingNCT05998928Phase 2
- Prospective Cohort of Single-dose Radiotherapy for Painful Bone Lesions in Multiple MyelomaRecruitingNCT05996367Not applicable